David Egilman, Gregory Collins, Julie Falender, Naomi Shembo, Ciara Keegan, Sunil Tohan

David Egilman is a Clinical Professor of Family Medicine at Brown University. He is board-certified in internal medicine and preventive and occupational medicine and an epidemiologist, and the past Editor in Chief of the International Journal of Occupational and Environmental Health and current Editor of The Journal of Scientific Practice and Integrity.

The Rise of the Opioids: How Purdue Invented New Markets for OxyContin

Purdue's strategy was to market its opioids directly to patients via brochures, videos, advertisements, and the internet. It also provided information to doctors and...

Purdue Circumvented the Regulator to Promote OxyContin, Hiding Its Real Risk of Addiction

In 2001, the Food and Drug Administration required Purdue to change OxyContin’s patient package inserts to make addiction risks more evident. The company altered...

OxyContin's Academic Marketing: The Studies That Fueled the Opioid Crisis

Purdue Pharmaceuticals used to cite three major studies to argue that in prescribing OxyContin, addiction-risk was not significant. The most influential of those studies...

Latest news

George Stigler on Henry Simons, “Crown Prince” of the Chicago School

To mark 75 years since the passing of Henry Simons, professor of Economics and Law at the University of Chicago, ProMarket is...

Electoral College Reform: New Problems or Real Solutions?

Each electoral system creates specific incentives to (mis)allocate government resources. Would putting the National Popular Vote (NPV) in lieu of the Electoral...

When Do Users Benefit From Platform Mergers?

A new paper shows that platform mergers can harness network effects at the cost of reducing the platform differentiation that users value. 

Harold Demsetz and Israel Kirzner Understood That Competition Regulates Markets

Economists Harold Demsetz and Israel Kirzner challenged the prevailing orthodoxy in microeconomic analysis and public policy beginning with their respective work in...

The Covid-19 Pandemic Should Not Delay Actions to Prevent Anticompetitive Consolidation in US Health Care Markets

Harvard Business School professor Leemore Dafny lays out potential reforms to assist agencies in halting anticompetitive acquisitions and practices, and to preserve...

Who Benefits From Competitive State-Level Legislatures?

A new paper finds that when interparty competition in state legislatures is high, well-connected and influential incumbent firms are best able to...

No More “Mystery Meat”: Why We Need Better Corporate Governance Data

Three decades of finance, economics, and legal studies in corporate governance have been built substantially on data sets with nearly unknown provenance....